ReviewFrontiers in immunology2015
Novel Immune Check-Point Regulators in Tolerance Maintenance.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Alteration in sB7-H4 Serum Levels and Placental Biomarker Expression after Therapeutic Plasma Exchange in Early-Onset Preeclampsia Patients.International journal of molecular sciences · 2024Article
- Review
- Combination of vitamin D and photodynamic therapy enhances immune responses in murine models of squamous cell skin cancer.Photodiagnosis and photodynamic therapy · 2024Article
- NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.International journal of biological sciences · 2024Article
- Combination of 5-Fluorouracil with Photodynamic Therapy: Enhancement of Innate and Adaptive Immune Responses in a Murine Model of Actinic KeratosisPhotochemistry and photobiology · 2023Review
- Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection.Frontiers in immunology · 2023Review
- Morbid Obesity in Women Is Associated with an Altered Intestinal Expression of Genes Related to Cancer Risk and Immune, Defensive, and Antimicrobial Response.Biomedicines · 2022Article
- Article
- BTN2A2 protein negatively regulates T cells to ameliorate collagen-induced arthritis in mice.Scientific reports · 2021Article
- ERMAP is a B7 family-related molecule that negatively regulates T cell and macrophage responses.Cellular & molecular immunology · 2021Article
- Cell-type-specific expression quantitative trait loci associated with Alzheimer disease in blood and brain tissue.Translational psychiatry · 2021Article
- Neonatal genetics of gene expression reveal potential origins of autoimmune and allergic disease risk.Nature communications · 2020Article
- Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.BMC medical genomics · 2020Article
- B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.Frontiers in oncology · 2020Article
- Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).Advances in therapy · 2019Review
- Skint8, a Novel B7 Family-Related Molecule, Negatively Regulates T Cell Responses.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- BTNL2-Ig Protein Attenuates Type 1 Diabetes in Non-Obese Diabetic (NOD) Mice.Advanced healthcare materials · 2019Article
- In vivo administration of recombinant BTNL2-Fc fusion protein ameliorates graft-versus-host disease in mice.Cellular immunology · 2019Article
- Prediction of Disordered Regions and Their Roles in the Anti-Pathogenic and Immunomodulatory Functions of Butyrophilins.Molecules (Basel, Switzerland) · 2018Article
- Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.Oncology letters · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The great success of anti-cytotoxic lymphocyte antigen 4 (CTLA4) and anti-programed cell death protein 1 (PD1) in cancer treatment has encouraged more effort in harnessing the immune response through immunomodulatory molecules in various diseases. The immunoglobulin (Ig) super family comprises the majority of immunomodulatory molecules. Discovery of novel Ig super family members has brought novel insights into the function of different immune cells in tolerance maintenance. In this review, we discuss the function of newly identified B7 family molecules, B7-H4 and V-domain Ig Suppressor of T cell Activation (VISTA), and the butyrophilin/butyrophilin-like family members. We discuss the current stages of immunomodulatory molecules in clinical trials of organ transplantation. The potential of engaging the novel Ig superfamily members in tolerance maintenance is also discussed. We conclude with the challenges remaining to manipulate these molecules in the immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.